Literature DB >> 25345614

Polo-like kinase 1 as a potential therapeutic target for osteosarcoma.

Li Cheng, Chongchong Wang, Juehua Jing.   

Abstract

Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. Existing treatment options and surgical intervention are unable to effectively manage this tumor. Therefore, novel mechanism-based targets and strategies need to be rationally established to strive for improvement in the survival of patients diagnosed with osteosarcoma. The serine/threonine kinases Polo-like kinase (Plk) 1 is a key regulator of cell division in eukaryotic cells. Plk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, we shall discuss the studies which indicate that Plk1 could be an excellent target for the treatment of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25345614     DOI: 10.2174/1381612820999141029162811

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

2.  α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer.

Authors:  Jinku Zhang; Yanan Wang; Jinmei Li; Wenming Zhao; Zhao Yang; Yanguang Feng
Journal:  RSC Adv       Date:  2020-02-03       Impact factor: 4.036

3.  Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni.

Authors:  Thavy Long; R Jeffrey Neitz; Rachel Beasley; Chakrapani Kalyanaraman; Brian M Suzuki; Matthew P Jacobson; Colette Dissous; James H McKerrow; David H Drewry; William J Zuercher; Rahul Singh; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2016-01-11

4.  Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy.

Authors:  Li Cheng; Youqun Ke; Shuisheng Yu; Juehua Jing
Journal:  Int J Nanomedicine       Date:  2016-10-25

5.  Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma.

Authors:  Weiqiang Fan; Huan Ma; Bin Jin
Journal:  Oncol Lett       Date:  2022-03-15       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.